References
- NEWSOM SWB: Cefotaxhne for urinary tract infection. J. Antimicrob. Chemotber. (1980) 6(Suppl. A):199–203.
- KUMAMOTO Y, NISHIO A: C,efotaxime treatment of com-plicated urinary tract infection. J. Antimicrob. Chemother. (1980) 6(Suppl. A):205.
- KAWADA Y, SHIMIZU Y, NISHURA T: Comparative studies of cefotaxime and sulbendllin in complicated urinary tract infection. J. Antimicrob. Cbemotber. (1980) 6(Suppl. A):213–218.
- NEWSOM SWB, MATTHEWS J, AMPHLETT M, WARREN RE: The microbial activity of norfloxadn. Cbemioterapia (1982) 1(Suppl.):70.
- KUMAMOTO Y: Clinical experience with norfloxadn in urinary tract infections. Cbemioterapia (1982) 1(Suppl.):70–71.
- BAILEY RR: Single dose treatment for uncomplicated UTIs. Drugs (1979) 17:219–221.
- OKOSHI M, KAWADA Y (Eds.): Clinical Evaluation of cirug efficacy in UTL Exceipta Medica, International Congress Series 938. Amsterdam, 1990.
- OKOSHI M, NABER KG (Eds.): International consensusdiscussion on clinical evaluation of drug efficacy in urinary tract infection. Infection (1992) 20\(Suppl. 3).
- NORRBY SR: Quality of antibiotic clinical trials. J. Antimi-crab. Cbentotber. (1984) 14:205–208.
- GILBERT DN, BEAM TR, ICUNIN CM: The implications forEurope of revised FDA guidelines for clinieni trials of anti-infective agents. Eur. J. Clin. Microbiol. Infect. Dis. (1990) 9:552–558.
- LUNDE I: Guidelines of the World Health Organisation for clinical trials of anti-infective agents. Eur. J. Clin. Microbiol. Infect. Dis. (1990) 9:548–551.
- HU111–1.LT B: Statistical aspects of clinical trials of anti-biotics in acute infections. Rev. Infect. Dis. (1986) 8\(Suppl. 3):S350–357.
- RUBIN RH, SHAPIRO ED, ANDRIOLE V, DAVIS RJ, STAMM WE: Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Clin. Infect. Dis. (1992) 15\(Suppl. 1):S216–227.
- KUNIN CM: Guidelines for evaluation of new anti-infec-tive drugs for the treatment of urinary tract infection: additional considerations. Clin. Infect. Dis. (1992) 15:1041–1044.